nach oben

International Journal of Hematology

Erschienen in:

10.04.2019 | Case Report

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series

verfasst von: Jacqueline N. Poston, Terry B. Gernsheimer

Erschienen in: International Journal of Hematology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These patients were previously treated with a median of 6 therapies. One patient elected to discontinue both medications despite persistent thrombocytopenia. The remaining 9 patients continued on the combination of prednisone (doses 5 mg every other day to 10 mg daily) and a TPO-RA. Combination therapy with low dose glucocorticoid and a TPO-RA may be an option for patients unresponsive to a TPO-RA alone.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23. https://doi.org/10.1111/bjh.12260.CrossRefPubMed

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45. https://doi.org/10.1182/blood-2012-04-425512.CrossRefPubMed

Rashidi A, Blinder MA. Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review. J Clin Pharm Ther. 2016;41(5):453–8. https://doi.org/10.1111/jcpt.12421.CrossRefPubMed

Arnold DM, Nazi I, Santos A, Chan H, Heddel NM, Warkentin TE, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29–31. https://doi.org/10.1182/blood-2009-06-222448.CrossRefPubMed

Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331–4. https://doi.org/10.1097/MBC.0b013e3283513a97.CrossRefPubMed

Yoon JS, Lee YJ, Baek DW, Park HY, Park BE, Moon JH, et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean J Intern Med. 2018;33(2):435–7. https://doi.org/10.3904/kjim.2015.252.CrossRefPubMed

Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus. 2014;12(Suppl 1):s149–50. https://doi.org/10.2450/2013.0289-12.CrossRefPubMedPubMedCentral

Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Perez JC, Gomez-De Leon A, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–8. https://doi.org/10.1182/blood-2014-01-549360.CrossRefPubMed

Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–8.PubMed

10.

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65. https://doi.org/10.1517/14740338.2016.1140743.CrossRefPubMed

11.

Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Eur J Haematol. 2016;97(1):101–3. https://doi.org/10.1111/ejh.12733.CrossRefPubMed

12.

Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood. 1978;51(5):771 LP–779.

13.

Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW × BXSB) F1. Blood. 1992;79(4):942–7.PubMed

14.

Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–80. https://doi.org/10.1056/NEJM198904133201505.CrossRefPubMed

Titel: Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
verfasst von: Jacqueline N. Poston
Terry B. Gernsheimer
Publikationsdatum: 10.04.2019
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 2/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-019-02638-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma

Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan

Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia

Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie